Endocrine-based therapies such as ER-blockade, oestrogen synthesis inhibition, and selective ER degradation are used to treat most ER + cancers since ER is the primary oncogenic driver (Zardo et al., 2003; Thomas and Potter, 2013). The gene discussed is ESR1; the disease is cancer.